Invikafusp alfa - Marengo Therapeutics
Alternative Names: STAR-0602Latest Information Update: 13 Jan 2025
Price :
$50 *
At a glance
- Originator Marengo Therapeutics
- Class Antibodies; Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 08 Jan 2025 Invikafusp alfa - Marengo Therapeutics receives Fast Track designation for Colorectal cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV,Infusion)
- 20 Dec 2024 Phase-II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Spain, France (IV)
- 09 Nov 2024 Interim adverse events and efficacy data from a phase-I/II trial in Solid tumours released by Marengo Therapeutics ,